Shares of Harrow, Inc. (NASDAQ:HROW - Get Free Report) fell 4.9% during trading on Wednesday . The company traded as low as $34.59 and last traded at $34.35. 202,454 shares changed hands during mid-day trading, a decline of 32% from the average session volume of 295,937 shares. The stock had previously closed at $36.10.
Analyst Upgrades and Downgrades
Several research analysts have recently issued reports on HROW shares. Lake Street Capital raised their target price on shares of Harrow from $45.00 to $55.00 and gave the company a "buy" rating in a research note on Friday, October 4th. B. Riley cut their price target on Harrow from $73.00 to $69.00 and set a "buy" rating on the stock in a research note on Wednesday, December 4th. Finally, Craig Hallum lifted their price objective on Harrow from $45.00 to $65.00 and gave the stock a "buy" rating in a research note on Friday, October 4th.
Check Out Our Latest Stock Report on Harrow
Harrow Stock Performance
The firm has a market capitalization of $1.23 billion, a price-to-earnings ratio of -36.76 and a beta of 0.72. The stock's fifty day moving average is $37.79 and its two-hundred day moving average is $39.02. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23.
Institutional Trading of Harrow
A number of institutional investors and hedge funds have recently made changes to their positions in HROW. Quest Partners LLC bought a new stake in shares of Harrow during the 3rd quarter worth approximately $29,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in Harrow by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,283 shares of the company's stock valued at $57,000 after purchasing an additional 227 shares during the last quarter. Hills Bank & Trust Co bought a new position in Harrow in the 3rd quarter valued at approximately $107,000. Huntington National Bank bought a new position in Harrow in the 3rd quarter valued at approximately $164,000. Finally, Clarus Group Inc. acquired a new position in Harrow in the 3rd quarter valued at approximately $225,000. Institutional investors own 72.76% of the company's stock.
About Harrow
(
Get Free Report)
Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Harrow, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harrow wasn't on the list.
While Harrow currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
